| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
41,611 |
34,523 |
$2.34M |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
3,983 |
3,522 |
$320K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
2,973 |
2,745 |
$252K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
2,653 |
2,377 |
$211K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
7,899 |
7,164 |
$208K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
2,063 |
1,810 |
$176K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
838 |
666 |
$65K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
4,864 |
2,107 |
$59K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
4,168 |
3,807 |
$53K |
| 90461 |
|
4,714 |
4,389 |
$42K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
265 |
243 |
$27K |
| 96127 |
|
4,498 |
2,394 |
$15K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
383 |
359 |
$14K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
212 |
196 |
$13K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
326 |
298 |
$13K |
| 92551 |
|
1,426 |
1,239 |
$11K |
| 99050 |
|
698 |
647 |
$9K |
| 99381 |
|
66 |
57 |
$5K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
373 |
333 |
$5K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
166 |
120 |
$3K |
| 87807 |
|
278 |
260 |
$3K |
| 99173 |
|
1,249 |
1,102 |
$3K |
| 87420 |
|
341 |
278 |
$3K |
| 81002 |
|
1,044 |
903 |
$3K |
| 0071A |
|
110 |
103 |
$3K |
| 90677 |
|
139 |
128 |
$2K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
186 |
108 |
$2K |
| 90697 |
|
276 |
246 |
$2K |
| 85018 |
|
1,094 |
995 |
$2K |
| 92587 |
|
63 |
63 |
$795.58 |
| 83655 |
|
82 |
65 |
$770.35 |
| 90710 |
|
758 |
694 |
$693.01 |
| 90670 |
|
2,880 |
2,710 |
$607.52 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
36 |
33 |
$386.84 |
| 81000 |
|
172 |
139 |
$317.01 |
| 96160 |
|
138 |
128 |
$234.84 |
| 99441 |
|
31 |
13 |
$183.98 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
92 |
66 |
$124.67 |
| 85014 |
|
81 |
77 |
$121.65 |
| 90715 |
|
212 |
194 |
$91.69 |
| 90696 |
|
126 |
120 |
$75.20 |
| 90686 |
|
649 |
586 |
$57.03 |
| 90723 |
|
422 |
395 |
$50.40 |
| 99177 |
|
28 |
28 |
$4.73 |
| 90649 |
|
248 |
218 |
$1.12 |
| 90648 |
|
838 |
783 |
$0.86 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
374 |
334 |
$0.42 |
| 90698 |
|
660 |
632 |
$0.00 |
| 99000 |
|
71 |
68 |
$0.00 |
| 90744 |
|
175 |
165 |
$0.00 |
| 36416 |
|
159 |
138 |
$0.00 |
| 97802 |
|
26 |
26 |
$0.00 |
| 91307 |
|
72 |
66 |
$0.00 |
| 94760 |
|
15 |
13 |
$0.00 |
| 90681 |
|
642 |
611 |
$0.00 |
| 90633 |
|
30 |
27 |
$0.00 |
| 90700 |
|
40 |
36 |
$0.00 |